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A B S T R A C T
Background
There is inconclusive evidence from observational studies to suggest that people who eat a diet rich in antioxidant vitamins (carotenoids,
vitamins C, and E) or minerals (selenium and zinc) may be less likely to develop age-related macular degeneration (AMD).
Objectives
To determine whether or not taking antioxidant vitamin or mineral supplements, or both, prevent the development of AMD.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials
Register) (2017, Issue 2), MEDLINE Ovid (1946 to 29 March 2017), Embase Ovid (1947 to 29 March 2017), AMED (Allied and
Complementary Medicine Database) (1985 to 29 March 2017), OpenGrey (System for Information on Grey Literature in Europe) (
www.opengrey.eu/); searched 29 March 2017, the ISRCTN registry (www.isrctn.com/editAdvancedSearch); searched 29 March 2017,
ClinicalTrials.gov (www.clinicaltrials.gov); searched 29 March 2017 and the WHO International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en); searched 29 March 2017. We did not use any date or language restrictions in the electronic
searches for trials.
Selection criteria
We included all randomised controlled trials (RCTs) comparing an antioxidant vitamin ormineral supplement (alone or in combination)
to control.
Data collection and analysis
Both review authors independently assessed risk of bias in the included studies and extracted data. One author entered data into RevMan
5; the other author checked the data entry. We pooled data using a fixed-effect model. We graded the certainty of the evidence using
GRADE.
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Main results
We included a total of five RCTs in this review with data available for 76,756 people. The trials were conducted in Australia, Finland,
and the USA, and investigated vitamin C, vitamin E, beta-carotene, and multivitamin supplements. All trials were judged to be at low
risk of bias.
Four studies reported the comparison of vitamin E with placebo. Average treatment and follow-up duration ranged from 4 to 10 years.
Data were available for a total of 55,614 participants. There was evidence that vitamin E supplements do not prevent the development
of any AMD (risk ratio (RR) 0.97, 95% confidence interval (CI) 0.90 to 1.06; high-certainty evidence), and may slightly increase
the risk of late AMD (RR 1.22, 95% CI 0.89 to 1.67; moderate-certainty evidence) compared with placebo. Only one study (941
participants) reported data separately for neovascular AMD and geographic atrophy. There were 10 cases of neovascular AMD (RR
3.62, 95% CI 0.77 to 16.95; very low-certainty evidence), and four cases of geographic atrophy (RR 2.71, 95% CI 0.28 to 26.0;
very low-certainty evidence). Two trials reported similar numbers of adverse events in the vitamin E and placebo groups. Another trial
reported excess of haemorrhagic strokes in the vitamin E group (39 versus 23 events, hazard ratio 1.74, 95% CI 1.04 to 2.91, low-
certainty evidence).
Two studies reported the comparison of beta-carotene with placebo. These studies took place in Finland and the USA. Both trials
enrolled men only. Average treatment and follow-up duration was 6 years and 12 years. Data were available for a total of 22,083
participants. There was evidence that beta-carotene supplements did not prevent any AMD (RR 1.00, 95% CI 0.88 to 1.14; high-
certainty evidence) nor have an important effect on late AMD (RR 0.90, 95% CI 0.65 to 1.24; moderate-certainty evidence). Only
one study (941 participants) reported data separately for neovascular AMD and geographic atrophy. There were 10 cases of neovascular
AMD (RR 0.61, 95% CI 0.17 to 2.15; very low-certainty evidence) and 4 cases of geographic atrophy (RR 0.31 95% CI 0.03 to 2.93;
very low-certainty evidence). Beta-carotene was associated with increased risk of lung cancer in people who smoked.
One study reported the comparison of vitamin C with placebo, and multivitamin (Centrum Silver) versus placebo. This was a study
in men in the USA with average treatment duration and follow-up of 8 years for vitamin C and 11 years for multivitamin. Data were
available for a total of 14,236 participants. AMD was assessed by self-report followed by medical record review. There was evidence
that vitamin C supplementation did not prevent any AMD (RR 0.96, 95% CI 0.79 to 1.18; high-certainty evidence) or late AMD
(RR 0.94, 0.61 to 1.46; moderate-certainty evidence). There was a slight increased risk of any AMD (RR 1.21, 95% CI 1.02 to 1.43;
moderate-certainty evidence) and late AMD (RR 1.22, 95% CI 0.88 to 1.69; moderate-certainty evidence) in the multivitamin group.
Neovascular AMD and geographic atrophy were not reported separately. Adverse effects were not reported but there was possible
increased risk of skin rashes in the multivitamin group.
Adverse effects were not consistently reported in these eye studies, but there is evidence from other large studies that beta-carotene
increases the risk of lung cancer in people who smoke or who have been exposed to asbestos.
None of the studies reported quality of life or resource use and costs.
Authors’ conclusions
Taking vitamin E or beta-carotene supplements will not prevent or delay the onset of AMD. The same probably applies to vitamin
C and the multivitamin (Centrum Silver) investigated in the one trial reported to date. There is no evidence with respect to other
antioxidant supplements, such as lutein and zeaxanthin. Although generally regarded as safe, vitamin supplements may have harmful
effects, and clear evidence of benefit is needed before they can be recommended. People with AMD should see the related Cochrane
Review on antioxidant vitamin and mineral supplements for slowing the progression of AMD, written by the same review team.
P L A I N L A N G U A G E S U M M A R Y
Antioxidant vitamin and mineral supplements to prevent the development of age-related macular degeneration (AMD)
What is the aim of this review?
The aim of this Cochrane Reviewwas to find outwhether taking antioxidant vitamin andmineral supplements prevents the development
of AMD. Cochrane researchers collected and analysed all relevant studies to answer this question and found five studies.
Key messages
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Taking vitamin E or beta-carotene supplements will not prevent the onset of AMD in people who do not have signs of the condition.
The same probably applies to vitamin C and multivitamin tablets. There is no evidence for other supplements, such as lutein and
zeaxanthin.
What was studied in the review?
AMD is a condition of the central area (macula) of the back of the eye (retina). The macula degenerates with age. In some people,
this deterioration happens more quickly, and is associated with a particular appearance at the back of the eye. In its earliest stage (early
AMD), yellow spots (drusen) can be seen under the retina by an eye health professional on examining the eye. The affected person will
probably be unaware that they have a problem. As AMD progresses, it can lead to the loss of the cells in the back of the eye, which
are needed for vision. This is known as geographic atrophy. Sometimes, new (harmful) blood vessels grow in the macula. These new
blood vessels may bleed and cause scarring. This is known as neovascular or wet AMD. Any damage to the macula can affect vision,
particularly central vision. Neovascular AMD and geographic atrophy are known as late AMD.
It is possible that antioxidant vitamins may help to protect the macula against this deterioration and loss of vision. Vitamin C, E, beta-
carotene, lutein, zeaxanthin, and zinc are examples of antioxidant vitamins commonly found in vitamin supplements.
The Cochrane researchers only looked at the effects of these supplements in healthy people in the general population who did not yet
have AMD. There is another Cochrane Review on the effects of these supplements in people who already have AMD.
What are the main results of the review?
The Cochrane researchers found five relevant studies. The studies were large and included a total of 76,756 people. They took place
in Australia, Finland, and the USA. The studies compared vitamin C, vitamin E, beta-carotene, and multivitamin supplements with
placebo.
The review showed that, compared with taking a placebo:
Taking vitamin E supplements made little or no difference to the chances of developing AMD (high-certainty evidence).
Taking vitamin E supplements made little difference, or slightly increased, the chances of developing late AMD (moderate-certainty
evidence).
Taking beta-carotene made little or no difference to the chances of developing any AMD (high-certainty evidence) or late AMD
(moderate-certainty evidence).
Taking vitamin C made little or no difference to the chances of developing any AMD (high-certainty evidence) or late AMD
(moderate-certainty evidence).
Taking multivitamin tablets may slightly increase the chances of developing any AMD or late AMD (moderate-certainty evidence).
Adverse effects were not consistently reported in these eye studies, but there is evidence from other large studies that beta-carotene
increases the risk of lung cancer in people who smoke, or who have been exposed to asbestos.
None of the studies reported quality of life or resource use and costs.
How up-to-date is this review?
The Cochrane researchers searched for studies that had been published up to 29 March 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Vitamin E versus placebo
Patient or population: general populat ion
Setting: community
Intervention: vitamin E*
Comparison: placebo
Outcomes Anticipated absolute effects (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo* * Risk with vitamin E
Any AMD 150 per 1000 146 per 1000
(135 to 159)
RR 0.97
(0.90 to 1.06)
55,614
(4 RCTs)
⊕⊕⊕⊕
HIGH
Average durat ion of
treatment and follow-
up ranged f rom 4 years
to 10 years
Late AMD (either neo-
vascular AMD or ge-
ographic atrophy or
both)
5 per 1000 6 per 1000
(4 to 8)
RR 1.22
(0.89 to 1.67)
55,614
(4 RCTs)
⊕⊕⊕©
MODERATE 1
Average durat ion of
treatment and follow-
up ranged f rom 4 years
to 10 years
Neovascular AMD 3 per 1000 11 per 1000
(2 to 51)
RR 3.62
(0.77 to 16.95)
941
(1 RCT)
⊕©©©
VERY LOW 2
Average durat ion of
treatment and follow-
up was 6 years
Geographic atrophy 2 per 1000 6 per 1000
(1 to 57)
RR 2.71
(0.28 to 26.00)
941
(1 RCT)
⊕©©©
VERY LOW 2
Average durat ion of
treatment and follow-
up was 6 years
Quality of lif e - - - - - Not reported
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Adverse ef fects (AE) - - - - ⊕⊕©©
LOW3
Two trials reported sim-
ilar numbers of AEs in
vitamin E and placebo
group. Another trial re-
ported excess of haem-
orrhagic strokes in vita-
m in E group (39 vs 23
events, hazard rat io 1.
74, 95% CI 1.04 to 2.91)
Resource use and costs - - - - - Not reported
* Dose of vitamin E used in studies were: 50 mg/ day, 400 IU/ alternate days, 600 IU/ alternate days, and 500 IU/ day
* * The risk in the placebo group is the median risk in the placebo groups in the included studies. The risk in the intervention group (and its 95% conf idence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate-certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low-certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level for imprecision due to wide conf idence intervals i.e. are below 0.8 or above 1.25.
2 Downgraded one level for indirectness (only one trial in male smokers) and downgraded two levels for imprecision as very
few cases (10 neovascular AMD, 4 geographic atrophy)
3 Downgraded one level for imprecision due to wide conf idence intervals and lower conf idence near 1 and downgraded one
level for inconsistency as ef fect only reported by one trial.
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B A C K G R O U N D
Description of the condition
Age-relatedmacular degeneration (AMD) is a disease affecting the
central area of the retina (macula). In the early stages of the dis-
ease, lipid material accumulates in deposits underneath the reti-
nal pigment epithelium. These deposits are known as drusen, and
can be seen as pale yellow spots on the retina. The pigment of
the retinal pigment epithelium may become disturbed, with areas
of hyperpigmentation and hypopigmentation. In the later stages
of the disease, the retinal pigment epithelium may atrophy com-
pletely. This loss can occur in small focal areas or be widespread
(geographic). In some cases, new blood vessels grow under the
retinal pigment epithelium, and occasionally, into the subretinal
space (exudative or neovascular AMD). Haemorrhage can occur,
which often results in increased scarring of the retina.
The early stages of the disease are, in general, asymptomatic. In the
later stages, theremay be considerable distortionwithin the central
visual field, leading to a complete loss of central visual function.
Population-based studies suggest that, in people 65 years andolder,
approximately 5% have advanced AMD (Owen 2012). It is the
most common cause of blindness and visual impairment in indus-
trialised countries. In the UK, for example, over 30,000 people
are registered as blind or partially sighted annually, half of whom
have lost their vision due to macular degeneration (Bunce 2006).
Description of the intervention
Photoreceptors in the retina are subject to oxidative stress through-
out life, due to combined exposures to light and oxygen. It has
been proposed that antioxidants may prevent cellular damage in
the retina by reacting with free radicals produced in the process of
light absorption (Christen 1996).
There are a number of non-experimental studies that have exam-
ined the possible association between antioxidant micronutrients
and AMD, although few studies have examined supplementation
specifically (Chong 2007; Evans 2001). Data on vitamin intake
in observational studies should be considered cautiously, as people
who have a diet rich in antioxidant vitamins and minerals, or who
choose to take supplements regularly, are different in many ways
from those who do not; these differences may not be adequately
controlled by statistical analysis. The results of these observational
studies have been inconclusive.
How the intervention might work
The underlying theory is that antioxidant vitamin and mineral
supplements will protect the retina against oxidative stress, and
that this protection will delay the onset of AMD.
Why it is important to do this review
Antioxidant vitamin and mineral supplements are increasingly be-
ing marketed for use in age-related eye disease, including AMD.
The aim of this review was to examine the evidence on whether
taking vitamin or mineral supplements prevents the development
of AMD. See also the related Cochrane Review on antioxidant
vitamin and mineral supplements for slowing the progression
of AMD, which considered whether supplementation for people
with AMD slowed down the progression of the disease (Evans
2017).
O B J E C T I V E S
To determine whether or not taking antioxidant vitamin or min-
eral supplements, or both, prevent the development of AMD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) that compared
antioxidant vitamin or mineral supplements, (alone or in combi-
nation) with control (placebo or no treatment).
Types of participants
Participants in the trials were people in the general population,
with or without diseases other than AMD. We excluded trials in
which the participants were exclusively people with AMD. These
trials were considered in a separate Cochrane Review that exam-
ined the effect of supplementation on progression of the disease
(Evans 2017).
Types of interventions
Wedefined antioxidants as any vitamin ormineral that was known
to have antioxidant properties in vivo or which was known to
be an important component of an antioxidant enzyme present in
the retina. We considered the following: vitamin C, vitamin E,
carotenoids (including themacula pigment carotenoids lutein and
zeaxanthin), selenium and zinc.
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Types of outcome measures
We modified our protocol for the current update (2017) to in-
clude outcomes specified by the UK NICE macular degeneration
guideline panel (NICE 2016) - see Differences between protocol
and review.
We considered the following outcomes:
• Development of:
◦ any AMD (early or late AMD, or both)
◦ late AMD (neovascular AMD or geographic atrophy,
or both)
◦ neovascular AMD
◦ geographic atrophy
• Quality of life
• Resource use and costs
Follow-up:
We considered the maximum follow-up identified in the studies.
Adverse effects
We considered any adverse effects reported by the included studies.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist conducted
systematic searches in the following databases for randomised con-
trolled trials and controlled clinical trials. There were no language
or publication year restrictions. The date of the search was 29
March 2017.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 2) (which contains the Cochrane Eyes
and Vision Trials Register) in the Cochrane Library (searched 29
March 2017) (Appendix 1);
• MEDLINE Ovid (1946 to 29 March 2017) (Appendix 2);
• Embase Ovid (1980 to 29 March 2017) (Appendix 3);
• AMED (Allied and Complementary Medicine Database)
(1985 to 29 March 2017) (Appendix 4);
• OpenGrey (System for Information on Grey Literature in
Europe) (www.opengrey.eu/; searched 29 March 2017)
(Appendix 5);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch;
searched 29 March 2017) (Appendix 6);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov; searched 29 March
2017) (Appendix 7);
• World Health Organization International Clinical Trials
Registry Platform (www.who.int/ictrp; searched 29 March 2017)
(Appendix 8).
For the 2012 and 2017 updates, we specifically looked for ad-
verse effects, using a simple search aimed to identify systematic
reviews of adverse effects of vitamin supplements, see Appendix 9
for search strategy.
Searching other resources
We searched the Science Citation Index and the reference lists of
reports of trials that were selected for inclusion. We contacted the
investigators of included and excluded trials to ask if they knew of
any other relevant published or unpublished trials.
Data collection and analysis
Selection of studies
Our initial searches identified all trials of antioxidant supplements,
and therefore, generated many citations. Each review author in-
dependently assessed half of the titles and abstracts resulting from
the searches, and selected studies according to the definitions in
the Criteria for considering studies for this review. To check that
we were consistent, we both assessed a subset of 100 records and
compared results. We obtained full copies of all reports referring
to controlled trials that definitely or potentially met the inclusion
criteria. We assessed the full copies and selected studies according
to the inclusion criteria. We wrote to authors of trials for which
there were no published outcome data on AMD, to ask whether
they had collected any data on eye disease outcomes.
As none of the trial authors responded positively, i.e. gave us un-
published data on AMD, for further updates of this review we
only considered trials with published data on AMD.
In updates to this review, both authors independently went
through the titles and abstracts resulting from the searches, and
resolved disagreements by discussion.
Data extraction and management
We extracted data using methods’ forms developed by Cochrane
Eyes and Vision (eyes.cochrane.org/resources-review-authors).
We independently extracted data, and resolved disagreements by
discussion. One author cut and pasted the data into Review Man-
ager 5 (Review Manager 5 2014), and the other author checked
that this had been done correctly.
For the 2017 update, we screened and extracted data using web-
based review management software (Covidence 2015).
Assessment of risk of bias in included studies
Both authors independently assessed risk of bias using the
Cochrane tool for assessing risk of bias, as described in Chapter
8 of the Cochrane Handbook for Systematic Reviews of Interventions
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(Higgins 2011). We resolved disagreements by discussion. The re-
view authors were not masked to any trial details.
Measures of treatment effect
Our measure of treatment effect was the risk ratio (RR) for di-
chotomous outcomes and the mean difference (MD) for contin-
uous outcomes. Currently the review only includes analysis of di-
chotomous outcomes.
Unit of analysis issues
By definition, the interventions were applied to the person, but as
most people have two eyes, trials can analyse data fromone or both
eyes. In all the trials included in this review the unit of analysis
was the person and severity was classified for the worse eye.
Assessment of heterogeneity
We assessed heterogeneity by visual inspection of the forest plot,
the Chi² test for heterogeneity and the I² statistic.
Data synthesis
Where appropriate, we pooled data using a fixed-effect model,
after testing for heterogeneity between trial results using a standard
Chi² test.
Subgroup analysis and investigation of heterogeneity
We did not plan any subgroup analyses. Only five trials are in-
cluded at present, which means that it is not possible to formally
investigate heterogeneity.
Sensitivity analysis
We had planned to conduct sensitivity analyses to determine the
impact of study quality on effect size. Currently there are only
high-quality trials included in the review, and therefore, this is not
relevant at present.
’Summary of findings’ tables
We prepared separate ’Summary of findings’ tables for the differ-
ent types of vitamin supplement, i.e. vitamin C, vitamin E, beta-
carotene, and multivitamin.
We assessed the certainty of the evidence (GRADE) for each out-
come using customised software (GRADEpro 2014). JE did the
initial assessment, which was checked by JL.We considered risk of
bias, inconsistency, indirectness, imprecision, and publication bias
when judging the certainty of the evidence (Schünemann 2011).
The ’Summary of findings’ tables include an estimate of the risk
of each outcome in the general population. We derived these from
themedian risk in the placebo group in four of the studies included
in the review (ATBC 1998; PHS II 2012; VECAT 2002; WHS
2010). As there was overlap in participants between PHS I 2007
and PHS II 2012, we just used data from PHS II 2012 for this
estimate.
R E S U L T S
Description of studies
Results of the search
The initial searches resulted in 3178 titles and abstracts. Of these,
208 were potentially eligible trials reports. From these reports,
we identified seven primary prevention trials of antioxidant vi-
tamin or mineral supplements (ATBC 1994; CARET 1996; De
Klerk 1998; LINXIAN 1993; Nambour 1995; PHS I 2007;WHS
2010). Investigators from three trials have confirmed that they
did not collect data on AMD (CARET 1996; De Klerk 1998;
Nambour 1995).We excluded these trials from the review. We did
not receive a response from one trial author; we excluded this trial
(LINXIAN 1993). Three trials had published data on AMD out-
comes; we included them in this review (ATBC 1994; PHS I 2007;
WHS 2010). Search of the National Eye Institute Clinical Re-
search register identified one further ongoing trial that was collect-
ing information on AMD - the Women’s Antioxidant Cardiovas-
cular Study (WACS). There are two trials that have recruited par-
ticipants with and without AMD (AREDS 2001; VECAT 2002).
We included VECAT 2002 in this review because 82% of partic-
ipants did not have signs of AMD. We excluded AREDS 2001
because it did not include AMD outcomes for people without
AMD at baseline; it is included in the Cochrane Review exam-
ining the effect of supplementation on progression of the disease
(Evans 2017).
In our original search strategy, we identified all trials of antioxi-
dant interventions and asked trialists if they had collected data on
AMD. We wrote to the authors of 60 trials of antioxidant inter-
ventions in people with diseases other than AMD.We received 15
responses, and none had collected any relevant data. We included
all 60 trials in the excluded studies section of this review. As this
proved to be an inefficient way of identifying relevant trials, we
included terms for AMD in subsequent searches. We found 367
reports of trials in May 2002, 343 in May 2005, and 64 reports
in January 2006, but we did not identify any further trials that
were relevant for this review. The results of the PHS I study were
published in 2007.
We repeated the searches in August 2007, at which time we identi-
fied a total of 129 reports of studies. TheTrial SearchCo-ordinator
(TSC) scanned the search results and removed 84 references that
were not relevant to the scope of the review. We screened the titles
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and abstracts of the remaining 45 references and obtained full-
text copies of four reports to assess for potential inclusion in the
review. We identified one new report from the PHS I 2007 study
to include in the review and excluded the three remaining stud-
ies. For reasons of exclusion, see the ’Characteristics of excluded
studies’ table.
An update search was done in January 2012 which yielded 477
titles and abstracts. The TSC scanned the search results and re-
moved 206 references which were not relevant to the scope of the
review. We screened the title and abstracts of the remaining 271
references. We rejected 267 abstracts as not eligible for inclusion
in the review. We obtained full-text copies of four reports for fur-
ther examination. One new report from theWHS 2010 study has
been included in the review and three other studies were excluded.
For reasons of exclusion, see Characteristics of excluded studies.
Update searches run in March 2017 yielded a further 872 records
(Figure 1). After 157 duplicates were removed, the Cochrane In-
formation Specialist (CIS; formerly the Trial SearchCo-ordinator)
screened the remaining 715 records and removed 562 references
that were not relevant to the scope of the review. We screened
the remaining 153 references and obtained one full-text report for
further assessment, however, this study did not meet the inclusion
criteria. We checked the status of the ongoing studies published
in the previous version of this review. PHS II 2012 was now com-
pleted and we included it in this update. AREDS2 2008 was also
completed, however, this study did not meet the inclusion criteria;
see Characteristics of excluded studies for details.
9Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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Included studies
See the ’Characteristics of included studies’ table for more detailed
information.
Types of participants
The studies took place in Australia, USA, and Finland. Three
studies recruited men only (ATBC 1998; PHS I 2007; PHS II
2012), one study recruited women only (WHS 2010), and one
study recruited both men and women (VECAT 2002). There was
overlap of the participants in PHS I 2007 and PHS II 2012, as
some participants in PHS II 2012 were recruited from PHS I
2007.
People taking part in the trials were identified from the general
population. Participants in PHS I 2007 and PHS II 2012 were
male physicians, and in WHS 2010 were female health profes-
sionals. In ATBC 1998, a random sample of 1035 men aged 65
years or older from the main study were invited to participate,
with a response of 91% (941 men). In VECAT 2002, 18% of
participants had AMD at baseline.
Types of intervention
In ATBC 1998, the groups received either alpha-tocopherol 50
mg per day alone, beta-carotene 20 mg per day alone, alpha-
tocopherol and beta-carotene, or placebo. All formulations were
coloured with quinoline yellow. Treatment duration was five to
eight years (median 6.1 years). In VECAT 2002, participants were
randomised to vitamin E (500 IU a day) or placebo. Supplemen-
tation continued for four years. In PHS I 2007, the groups re-
ceived aspirin 325 mg every other day, beta-carotene 50 mg every
other day, aspirin and beta-carotene, or placebo. Treatment dura-
tion averaged 12 years. In PHS II 2012, participants received vi-
tamin C (500 mg daily), vitamin E (400 IU on alternate days), or
daily multivitamin (Centrum Silver), or corresponding placebos.
A beta-carotene arm was discontinued in 2003, and results not
reported. In WHS 2010, participants received vitamin E (600 IU
on alternate days) or placebo, and were followed up for 10 years.
Types of outcome measures
In ATBC 1998, three photographs of each eye were taken with
a Canon fundus camera at 40- and 60-degree angles on Kodak
Ektachrome 100 ASA slide film. These photographs were graded
by one observer, masked to the participant’s treatment group. The
following grades of maculopathy were used: 0 = none; I = dry
maculopathy with hard drusen, pigmentary changes, or both; II =
soft macular drusen; III = disciform degeneration; IV = geographic
atrophy.
In PHS I 2007, PHS II 2012, and WHS 2010, AMD was ascer-
tained by self report: “Have you ever hadmacular degeneration di-
agnosed in your right or left eye?”. If the participant answered yes
to this question, permission was gained to contact their ophthal-
mologist or optometrist, and further details were obtained from
the medical records.
In VECAT 2002, photographs were taken with a Nidek 3-DX
fundus camera on Kodachrome 64 ASA colour film. The pho-
tographs were graded at baseline independently by two trained
graders. Early AMD (the primary outcome) was defined as soft
drusen (distinct or indistinct) or pigmentary changes (hyperpig-
mentation or hypopigmentation) on photographic grading. On
clinical grading, this was large, soft drusen or non-geographical
retinal pigment epithelium atrophy. VECAT 2002 used Bailey-
Lovie visual acuity charts #4 and #5 (National Vision Research
Institute, Australia).
Table 1 shows how the AMD outcome measures in the included
studies were mapped onto the pre-specified review outcomes.
Excluded studies
See the ’Characteristics of excluded studies’ table for further in-
formation.
Risk of bias in included studies
We considered all five trials to be at low risk of bias (Figure 2;
Figure 3). See ’Risk of bias’ tables for each included study for
details of the assessment.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
See: Summary of findings for the main comparison Vitamin
E versus placebo; Summary of findings 2 Beta-carotene versus
placebo; Summary of findings 3 Vitamin C versus placebo;
Summary of findings 4Multivitamin versus placebo
See Table 1 for details of how the AMD outcomes reported in
the trials map to the review outcomes reported here. None of
the studies reported quality of life or resource use and costs. For
details of the GRADE assessments, see the ’Summary of findings’
tables (Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3; Summary of findings 4).
Vitamin E versus placebo
Summary of findings for the main comparison
Four studies reported this comparison (ATBC1998; PHS II 2012;
VECAT 2002; WHS 2010). These studies took place in Australia
(VECAT 2002), Finland (ATBC 1998), and USA (PHS II 2012;
WHS 2010). Men (ATBC 1998; PHS II 2012), women (WHS
2010), or both (VECAT 2002) were enrolled. Average treatment
and follow-up duration ranged from 4 years (VECAT 2002) to
10 years (WHS 2010). Data were available for a total of 55,614
participants.
The risk ratio for any AMDwas 0.97 (95%CI 0.90 to 1.06; high-
certainty evidence; Analysis 1.1) and for late AMDwas 1.22 (95%
CI 0.89 to 1.67; moderate-certainty evidence; Analysis 1.2).
Only one study (941 participants) reported data separately for
neovascular AMD and geographic atrophy (ATBC 1998). There
were 10 cases of neovascular AMD(RR 3.62, 9%% CI 0.77 to
16.95; very low-certainty evidence) and four cases of geographic
atrophy (RR 2.71, 95% CI 0.28 to 26.0; very low-certainty evi-
dence).
Beta-carotene versus placebo
Summary of findings 2
Two studies reported this comparison (ATBC 1998; PHS I 2007).
These studies took place in Finland (ATBC 1998), and USA (PHS
I 2007). Both trials enrolled men only. Average treatment and
follow-up duration was six years (ATBC 1998), and 12 years (PHS
I 2007). Data were available for a total of 22,083 participants.
The risk ratio for any AMDwas 1.00 (95%CI 0.88 to 1.14; high-
certainty evidence; Analysis 2.1), and 0.90 (95% CI 0.65 to 1.24;
moderate-certainty evidence; Analysis 2.2) for late AMD.
Only one study (941 participants) reported data separately for
neovascular AMD and geographic atrophy (ATBC 1998). There
were 10 cases of neovascular AMD(RR0.61, 95%CI0.17 to 2.15;
very low-certainty evidence) and four cases of geographic atrophy
(RR 0.31 95% CI 0.03 to 2.93; very low-certainty evidence).
Vitamin C versus placebo
Summary of findings 3
One study reported this comparison (PHS II 2012). PHS II 2012
was a study on men in the USA, with average treatment duration
and follow-up of eight years. Data were available for a total of
14,236 participants.
The risk ratio (RR) for any AMD was 0.96 (95% CI 0.79 to
1.18; high-certainty evidence) and for late AMD was 0.94 (0.61
to 1.46; moderate-certainty evidence; Analysis 3.1). The authors
also reported similar hazard ratios (HR), which were adjusted for
the other treatment assignments (vitamin E, beta-carotene, and
multivitamin treatment assignments). These HRs were 0.96 (0.78
to 1.18) for any AMD, and 0.94 (0.60 to 1.4) for late AMD.
Neovascular AMD and geographic atrophy were not reported sep-
arately.
Multivitamin versus placebo
Summary of findings 4
One study reported this comparison (PHS II 2012). This study
took place in the USA; they enrolled men only and followed them
up for an average of 11 years. Data were available for a total of
14,233 participants.
The risk ratio for any AMD was 1.21 (95% CI 1.02 to 1.43;
moderate-certainty evidence), and 1.22 (95% CI 0.88 to 1.69;
moderate certainty evidence; Analysis 4.1) for late AMD. The
authors also reported HRs, which were adjusted for the cohort
(PHS I and PHS II) and other treatment assignments (vitamin
C, vitamin E, and beta-carotene). These HRs were 1.22 (95% CI
1.03 to 1.44) for any AMD and 1.22 (95% CI 0.88 to 1.70) for
late AMD.
Neovascular AMD and geographic atrophy were not reported sep-
arately.
Adverse effects
Included studies
In general, the publications that reported eye outcomes did not
report adverse effects. We also looked at the reports of the main
study results for those trials where eye outcomes were collected as
part of a larger trial.
In VECAT 2002, it was noted that no serious adverse effects were
seen. Similar numbers of people in the vitamin E and placebo
groups withdrew due to adverse effects (four versus seven), re-
ported any adverse effect (91 versus 83), or ocular adverse effect
(105 versus 90).
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The main ATBC 1998 trial found an increased risk of lung cancer
associated with beta-carotene supplementation (ATBC 1994), a
finding that was repeated in the large CARET trial (Omenn 1996).
Beta-carotene supplementation is contra-indicated in people who
smoke or have been exposed to asbestos.
In the main WHS 2010 trial, “We examined whether vitamin E
increased adverse effects due to bleeding (gastrointestinal bleeding,
hematuria, easy bruising, epistaxis) because of the potential for
vitamin E to inhibit platelet function, gastrointestinal symptoms
(gastric upset, nausea, diarrhea, constipation), or fatigue. There
were no differences between reported adverse effects for any of
these variables among women in the two groups, apart from a
small, but significant, increase in the risk of epistaxis (RR 1.06,
95% CI 1.01 to 1.11; P = 0.02)” (Lee 2005).
InPHS II 2012, “An excess number of hemorrhagic strokeswas ob-
served among those assigned to vitamin E compared with placebo
(39 versus 23 events; HR 1.74, 95% CI 1.04 to 2.91)” (Gaziano
2009), and“We observed no significant differences in adverse ef-
fects, including hematuria, easy bruising, and epistaxis, for active
vitamin E or C compared with placebo”(Sesso 2008). For multivi-
tamins “...no significant effects on gastrointestinal tract symptoms
(peptic ulcer, constipation, diarrhea, gastritis, and nausea), fatigue,
drowsiness, skin discoloration, and migraine (all P > 0.05). Those
taking the active versus placebo multivitamin were more likely to
have skin rashes (2111 and 1973 men in corresponding active and
placebo multivitamin groups; HR 1.08, 95% CI 1.01 to 1.15; P =
0.016). In addition, there were inconsistent findings for daily mul-
tivitamin use on minor bleeding, with a reduction in hematuria
(998 and 1105 men in corresponding active and placebo multi-
vitamin groups; HR 0.89, 95% CI 0.81 to 0.97; P = 0.006), an
increase in epistaxis (1216 and 1106 men in corresponding active
and placebo multivitamin groups; HR 1.11, 95%CI 1.02 to 1.20;
P = 0.016), and no effect on easy bruising/other bleeding (1927
and 1902 men in corresponding active and placebo multivitamin
groups; HR 1.02, 95% CI 0.96 to 1.08; P = 0.59)” (Gaziano
2012).
Other systematic reviews
Reviews identified by the search in Appendix 9, for example,
Huang 2006, did not identify any consistent adverse effects of
mineral and vitamin supplements, but only included nine RCTs
in their review. A subsequent Cochrane Review including 78 trials
with 296,707 participants concluded “We found no evidence to
support antioxidant supplements for primary or secondary pre-
vention. Beta-carotene and vitamin E seem to increase mortality,
and so may higher doses of vitamin A” (Bjelakovic 2012).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Beta-carotene versus placebo
Patient or population: general populat ion
Setting: community
Intervention: beta-carotene*
Comparison: placebo
Outcomes Anticipated absolute effects (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo* * Risk with beta-
carotene
Any AMD 150 per 1000 150 per 1000
(132 to 171)
RR 1.00
(0.88 to 1.14)
22,083
(2 RCTs)
⊕⊕⊕⊕
HIGH
Average durat ion of
treatment and follow-
up was 6 years in one
study and 12 years in
the other study
Late AMD (either neo-
vascular AMD or ge-
ographic atrophy or
both)
5 per 1000 5 per 1000
(3 to 6)
RR 0.90
(0.65 to 1.24)
22,083
(2 RCTs)
⊕⊕⊕©
MODERATE 1
Average durat ion of
treatment and follow-
up was 6 years in one
study and 12 years in
the other study
Neovascular AMD 3 per 1000 2 per 1000
(1 to 6)
RR 0.61
(0.17 to 2.15)
941
(1 RCT)
⊕©©©
VERY LOW 2
Average durat ion of
treatment and follow-
up was 6 years
Geographic atrophy 2 per 1000 1 per 1000
(0 to 6)
RR 0.31
(0.03 to 2.93)
941
(1 RCT)
⊕©©©
VERY LOW 2
Average durat ion of
treatment and follow-
up was 6 years
Quality of lif e - - - - - Not reported
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Adverse ef fects - - - ⊕⊕⊕⊕
HIGH
Beta-carotene associ-
ated with increased risk
of lung cancer in people
who smoke
Resource use and costs - - - - - Not reported
* Dose of beta-carotene used was 20 mg/ day in one study and 50 mg/ alternate days in the other study
* * The risk in the placebo group is the median risk in the control groups of the four included studies in Summary of f indings for the main comparison. The risk in the
intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate-certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low-certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level for imprecision due to wide conf idence intervals i.e. are below 0.8 or above 1.25.
2 Downgraded one level for indirectness (only one trial in male smokers) and downgraded two levels for imprecision as very
few cases (10 neovascular AMD, 4 geographic atrophy)
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Vitamin C versus placebo
Patient or population: general populat ion
Setting: community
Intervention: vitamin C*
Comparison: placebo
Outcomes Anticipated absolute effects (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo* * Risk with vitamin C
Any AMD 150 per 1000 144 per 1000
(119 to 177)
RR 0.96
(0.79 to 1.18)
14,236
(1 RCT)
⊕⊕⊕⊕
HIGH
Average durat ion of
treatment and follow-
up was 8 years
Late AMD (either neo-
vascular AMD or ge-
ographic atrophy or
both)
5 per 1000 5 per 1000
(3 to 7)
RR 0.94
(0.61 to 1.46)
14,236
(1 RCT)
⊕⊕⊕©
MODERATE 1
Average durat ion of
treatment and follow-
up was 8 years
Neovascular AMD - - - - - Not reported
Geographic atrophy - - - - - Not reported
Quality of lif e - - - - - Not reported
Adverse ef fects - - - - None reported
Resource use and costs - - - - - Not reported
* Dose of vitamin C used was 500 mg/ day.
* * The risk in the placebo group is the median risk in the control groups of the four included studies in Summary of f indings for the main comparison. The risk in the
intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io
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GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate-certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low-certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level for imprecision due to wide conf idence intervals i.e. are below 0.8 or above 1.25.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Mult ivitamin versus placebo for prevent ing AMD
Patient or population: general populat ion
Setting: community
Intervention: mult ivitamin*
Comparison: placebo
Outcomes Anticipated absolute effects (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo* * Risk with multivitamin
Any AMD 150 per 1000 182 per 1000
(153 to 215)
RR 1.21
(1.02 to 1.43)
14,233
(1 RCT)
⊕⊕⊕©
MODERATE 1
Average durat ion of
treatment and follow-
up was 11 years
Late AMD 5 per 1000 6 per 1000
(4 to 8)
RR 1.22
(0.88 to 1.69)
14,233
(1 RCT)
⊕⊕⊕©
MODERATE 1
Average durat ion of
treatment and follow-
up was 11 years
Neovascular AMD - - - - - Not reported
Geographic atrophy - - - - - Not reported
Quality of lif e - - - - - Not reported
Adverse ef fects - - - - ⊕⊕⊕©
MODERATE 1
‘‘Those taking the ac-
t ive versus placebo
mult ivitamin were more
likely to have skin
rashes (2111 and 1973
men in corresponding
act ive and placebo mul-
t ivitamin groups; HR 1.
08, 95% CI 1.01 to 1.15;
P = 0.016)’’. PHS II
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Resource use and costs - - - - - Not reported
* Mult ivitamin used was Centrum Silver (zinc 15 mg, vitamin E 45 IU, vitamin C 60 mg, beta-carotene 5000 IU vitamin A, 20% as beta carotene, folic acid 2.5 mg, vitamin B6 50
mg, vitamin B12 1 mg)
* * The risk in the placebo group is the median risk in the control groups of the four included studies in Summary of f indings for the main comparison. The risk in the
intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate-certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low-certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level for imprecision
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D I S C U S S I O N
Summary of main results
This review provides evidence that people who take vitamin E or
beta-carotene supplements do not reduce their risk of developing
age-related macular degeneration (AMD; Summary of findings
for the main comparison; Summary of findings 2). There is more
limited evidence on vitamin C (Summary of findings 3), and one
multivitamin (Centrum Silver, Summary of findings 4), but at
present, nothing to suggest that these supplements prevent AMD.
Overall completeness and applicability of
evidence
This review includes five large, high-quality studies that ran-
domised over 75,000 members of the population to antioxi-
dant supplementation or placebo. Duration of supplementation
in these studies ranged from 4 to 12 years.
In ATBC 1994, there was no association with the treatment group
and development of early stages of the disease. If anything, there
was a tendency for more cases to be present in the treatment rather
than the placebo group. This was not statistically significant. One
drawback of adding a maculopathy study to a trial of primary
prevention is that we have no information on maculopathy status
before supplementation. Therefore, we have to assume that (1)
maculopathy was equally distributed across study groups at the
start of the study, and (2) most observed events occurred during
the study period. It is likely that this was true for a reasonable pro-
portion of the events, as the maculopathy study began eight years
after recruitment for the main trial, and randomisation should
have ensured equal distribution of maculopathy between the two
groups.
Supplementation in this study began at age 50 to 69 years and
lasted for five to eight years. Currently, we do not know at what
age antioxidant protection may be important. It may be that this
was too late or too short a period of supplementation to show
an effect. This study was conducted in Finnish male smokers,
and we have to be cautious in extrapolating the findings to other
geographical areas, to people in other age groups, to women, and
to non-smokers. However, the incidence of AMD, particularly
neovascular disease, is likely to be higher in smokers, which means
that they provide a good population to demonstrate any potential
protective effects of antioxidant supplementation (Klein 1993).
Similarly, the results of VECAT 2002 do not provide evidence of a
benefit of supplementation in people with no, mild, or borderline
AMD, although again, these studies have been underpowered to
examine late-stage disease.
In the PHS I 2007, over 20,000 physicians received supplementa-
tion with beta-carotene over 12 years. There was little evidence of
any benefit of beta-carotene supplementation. They used medical
record review to ascertain AMD, and therefore may have been less
accurate. However, there was no reason to suppose that the ascer-
tainment would have been different in the treatment and control
groups. The same method of ascertainment was used in PHS II
2012 and WHS 2010.
This review does not provide evidence on the effects of other
antioxidant vitamin andmineral supplements on the development
of AMD; in particular, it does not provide evidence on the effects
of commonly marketed vitamin combinations.
There are additional ongoing studies, including the Women’s an-
tioxidant cardiovascular study (WACS), and SELECT study that
are collecting data on AMD outcomes.
Although generally regarded as safe, antioxidant supplements may
have harmful effects. Our review does not provide a systematic re-
view of all possible adverse effects of supplements, but does high-
light the fact that beta-carotene increases the risk of lung cancer
and overall, there was some evidence of a small, increased risk of
mortality in people who took beta-carotene or vitamin E.
Quality of the evidence
Overall, the certainty of the evidence was considered to be high
for any AMD, moderate for late AMD (due to lower number of
events), and very low for neovascular AMDor geographic atrophy,
which were only reported disaggregated in one study.
Although the number of people randomised in these studies was
large, there is still a degree of uncertainty in the pooled estimates.
In the pooled analyses, the risk ratios were largely around the null
value, or just above the null value.
Potential biases in the review process
We did not include the Age-related Eye Disease Study in this re-
view. However, there were 2180 people recruited with no, mild, or
borderline AMD (AREDS 2001a). The study reported no benefit
of the study treatment for these people, however, the number of
events was small.
Agreements and disagreements with other
studies or reviews
A review of observational prospective studies in 2007 found little
evidence of a protective effect of dietary antioxidants (Chong
2007). The only dietary antioxidant forwhich a reductionwas seen
was vitamin E, in contrast to the evidence from the trials included
in this review. It is possible that natural vitamin E from dietary
sources rather than artificial supplements has different effects, or
alternatively, high levels of dietary vitamin E might be a marker
for other nutrients.
There are many reviews focusing on the role of antioxidant vita-
min and mineral supplements in people with AMD, but we have
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only identified one that considered specifically their role in healthy
people (Zampatti 2014). The conclusions were similar to the cur-
rent review that there is little evidence for any benefit in healthy
people.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Taking vitamin E or beta-carotene supplements will not prevent
or delay the onset of AMD. The same probably applies to vitamin
C and the multivitamin (Centrum Silver) investigated in the one
trial reported to date. There is no evidence with respect to other
antioxidant supplements, such as lutein and zeaxanthin.
Implications for research
There are a number of unanswered questions in the prevention of
AMD. The hypothesis that antioxidant micronutrients may pro-
tect against the disease is a reasonable one.We do not know at what
stage the protective effect may be important, nor the potential in-
teractions with genetic effects and other risk factors for the disease,
such as smoking. The research to date suggests that vitamin sup-
plements (at least those studied) do not prevent AMD. They do
not provide conclusive evidence on safety. The small number of
incident events in healthy people mean that any future trials need
to be very large. Four large primary and secondary prevention tri-
als in the field of cancer and cardiovascular disease have added an
examination of eye disease. This would seem to be a cost-effective
way forward in research in this area.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ATBC 1998
Methods Method of allocation: random. Sponsor provided coded capsules
Masking: participant: yes; provider: yes; outcome: yes
Exclusions after randomisation: no
Losses to follow-up: 31%. Random sample for maculopathy study: 9%.
2 x 2 factorial design. Maculopathy add-on random sample in 2 regions
Participants Country: Finland
Number of participants randomised: 29,133. Random sample of 1035 selected for mac-
ulopathy study
Age: 50 to 69 years in 1984. Maculopathy study 1992-3 in people aged 65 plus
Sex: male
Inclusion criteria: 5 or more cigarettes daily
Exclusion criteria: history of cancer or serious disease limiting ability to participate; those
taking supplements vitamin E, A, or beta-carotene in excess of predefined doses; those
treated with anticoagulants
Interventions Intervention:
• alpha-tocopherol (50 mg/day) N = 237
• beta-carotene (20 mg/day) N = 234
• alpha-tocopherol (50 mg/day) and beta-carotene (20 mg/day) N = 257
Comparator:
• placebo N = 213
Duration: 5 to 8 years (median 6.1)
Outcomes AMD: 4 grades:
Grade I: dry maculopathy with hard drusen, pigmentary changes, or both
Grade II: soft macular drusen
Grade III: disciform degeneration
Grade IV: geographic atrophy
Quote “A person was considered to have ARM if he had a class I or higher change in
either
eye, and severity was classified according to the worst eye.”
Notes Compliance with treatment excellent; 4/5 active participants took more than 95% of
scheduled capsules. Drop-out rate and compliance similar between all 4 groups
Funding source: Quote “This study was supported by the Juho Vainio Foundation,
Helsinki, Finland. The ATBC study was supported by Public Health Service Contract
N01-CN-45165 from the Division of Cancer Prevention and Control, National Cancer
Institute of the United States.”
Declarations of interest: NR
Date study conducted: Quote “The ophthalmological examination took place during
their final follow-up trial visit between December 1992 and March 1993”
Trial id: NCT00342992
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ATBC 1998 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “The participantswere randomly as-
signed to one of four treatment groups: AT
alone, AT and BC, BC alone, or placebo
in a complete 2 x 2 factorial design” and
“Randomization was performed in blocks
of eight within each of the study areas.”
Allocation concealment (selection bias) Low risk Quote “A coded reserve supply of capsule
packs...”
Not clearly stated that allocation concealed,
but the study was described as being “dou-
ble-blind”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Judgement comment: placebo-controlled
study.
Blinding of outcome assessment (detection
bias)
AMD
Low risk Quote “The retinal specialist [...] examined
six photographs (three per eye) of each par-
ticipant without knowledge of the subject’s
treatment group”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote “A total of 941 persons participated
(91%) and non-participation rates were
similar across the intervention groups.”
Selective reporting (reporting bias) Unclear risk Visual acuity measured but not reported,
but as the main results for AMD showed
no difference between groups, it is not clear
whether this was an example of selective
reporting or whether, in fact, the investi-
gators considered that visual acuity in this
age group might be attributed to a variety
of causes, and therefore, was not a relevant
outcome
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PHS I 2007
Methods Method of allocation: coded tablets
Masking: participant: yes; provider: yes; outcome: yes
99% follow-up
2 x 2 factorial design.
Participants Country: USA
Number randomised: originally 22,071 men were randomised:
21,142 participants were followed up for at least 7 years and provided information on
diagnoses of AMD made during the first 7 years of the trial
Age: 40 to 84 years in 1982
Sex: male
Inclusion criteria: physician aged 40 to 84 years in 1982 with no history of cancer,
myocardial infarction, stroke, or transient cerebral ischaemia
Exclusion criteria: personal history of cardiovascular disease or cancer; contraindications
or current use of study medication;
Interventions Intervention:
• beta-carotene (50 mg/alternate days) N = 11,036 randomised, 10,585 followed up
Comparator:
• beta-carotene placebo N = 11,035 randomised, 10,557 followed up
There was also an aspirin arm (2 x 2 factorial arm), which was terminated early (January
1988)
Mean duration 12 years range (range 11.6 to 14.2 years)
Outcomes Self report of AMD followed by medical record review and questionnaire to relevant
ophthalmologist
Primary endpoint: visually significant AMD, defined as a self-report confirmed by med-
ical record evidence of an initial diagnosis after randomisation, but before 31 December
1995, with a reduction in best-corrected visual acuity to 20/30 or worse attributable to
AMD
Secondary endpoints: AMD with or without vision loss, composed of all incident cases;
Advanced AMD, encompassed of cases of visually significant AMD with pathological
signs of disciform scar, RPE detachment, geographic atrophy, or subretinal neovascular
membrane
Quote “Individuals, rather than eyes, were the unit of analysis because eyes were not
examined independently, and participants were classified according to the status of the
worse eye as defined by disease severity. When the worse eye was excluded because of
visual acuity loss attributed to other ocular abnormalities the fellow eye was considered
for classification.”
Notes Funding source:Quote “Supported by research grantsHL26490,HL34595, CA 34944,
CA 40360, and EY 06633 from the National Institutes of Health”
Declarations of interest: NR
Date study conducted: August 1985 (from clinicaltrials.gov) to December 1995
Trial id: NCT00000500
Risk of bias
Bias Authors’ judgement Support for judgement
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PHS I 2007 (Continued)
Random sequence generation (selection
bias)
Low risk Quote “The PHS I was a randomised, dou-
ble-masked, placebo controlled trial...”
“A total of 22,071 physicians were then
randomised according to a two-by-two fac-
torial design, with use of a computer-gen-
erated list of random numbers...”
Allocation concealment (selection bias) Low risk Quote “The PHS I was a randomised, dou-
ble-masked, placebo controlled trial...”
Judgement Comment: Although this as-
pect of the trial was not well described, the
placebo control was described (placebo and
supplement identical appearance and pack-
aging) and the study was described as dou-
ble-blind
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote “The PHS I was a randomised, dou-
ble-masked, placebo controlled trial...”
Judgement Comment: Although this as-
pect of the trial was not well described, the
placebo control was described (placebo and
supplement identical appearance and pack-
aging) and the study was described as dou-
ble-blind
Blinding of outcome assessment (detection
bias)
AMD
Low risk Quote “The PHS I was a randomised, dou-
ble-masked, placebo controlled trial...”
Judgement Comment: Although this as-
pect of the trial was not well described,
the placebo control was described and the
study was described as double-blind. Di-
agnosis of AMD by self-report based on
health questionnaire (confirmed by oph-
thalmologist or optometrist). Patients and
researchers unaware of intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote “At the end of 11 years of follow-up
(the last year completed for all participants)
, 99.2%were still providing informationon
morbidity, and the follow-up for mortal-
ity was 99.9% complete. Eighty percent of
participants in the beta-carotene group and
in the placebo group were still taking the
study pills, with a mean compliance among
pill takers of more than 97%. Therefore,
even after 11 years, 78% of the study pills
assigned in the beta-carotene group were
reported as still being taken. In the placebo
group, 6% of participants reported taking
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PHS I 2007 (Continued)
supplemental beta carotene or vitamin A.”
Selective reporting (reporting bias) Low risk Judgement comment: reported AMD out-
comes as expected
PHS II 2012
Methods Method of allocation: coded tablets
Masking: participant: yes; provider: yes; outcome: yes
95% follow-up
2 x 2 x 2 x 2 factorial design.
Participants Country: USA
Number randomised: 14,236 with no diagnosis of AMDat baseline according to vitamin
C/E paper; 14,233 with no diagnosis of AMD at baseline according to multivitamin
paper
Average age: 64 years
Sex: male
Inclusion criteria: US male physicians; 50 years and older; participants in PHS I and
new physician participants; willing to forego use of supplements for new trial; for new
participants, do not report personal history of cancer (except non-melanoma skin cancer)
. CVD, current liver disease, current renal disease, peptic ulcer or gout. Compliance with
pill-taking regimen in run-in period
Exclusion criteria:History of cirrhosis; active liver disease in past six months; participants
reporting cataract or AMD at baseline
Interventions Intervention:
• vitamin E (400 IU/alternate days) N = 7112
• vitamin C (500 mg/day) N = 7149
• multivitamin (Centrum silver: zinc 15 mg, vitamin E 45 IU, vitamin C 60 mg,
beta-carotene 5000 IU, vitamin A - 20% as beta carotene, folic acid 2.5 mg, vitamin
B6 50 mg, vitamin B12 1 mg/ day) N = 7111
Comparator:
• separate placebos for each type of vitamin: vitamin E placebo N = 7124, vitamin
C placebo N = 7087, multivitamin placebo N = 7122
Alternate day beta-carotene (50 mg) component terminated in March 2003
Lutein (added to Centrum Silver during course of study (250 µg) and doses of other
nutrients changed
Follow-up: the multivitamin component had a longer duration.
“An average of 8 years of treatment and follow-up” for vitamin E and vitamin C
Median duration of treatment for multivitamin analyses 11.2 years, IQR 10.7 to 13.3
Outcomes Age-related macular degeneration: reported diagnosis followed up by contact with treat-
ing ophthalmologist/optometrist
Quote “We considered individuals, rather than eyes, as the unit of analysis and we
classified individuals according to the status of the worse eye as defined by disease severity.
When the worse eye was excluded because of visual acuity loss attributed to other ocular
abnormalities, the fellow eye was considered for classification.”
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PHS II 2012 (Continued)
Notes Funding source: Grants from National Eye Institute, National Institute on Ageing and
the National Institutes of Health. BASF and DSM provided study agents and packaging
Declarations of interest: “The authors have no proprietary or commercial interest in any
of the materials discussed in this article.”
Date study conducted: July 1997 to June 2011 (from clinicaltrials.gov)
Trial id: NCT00270647
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “Randomisation to the other agents,
using a computer generated list of random
numbers, will be stratified according to age”
Allocation concealment (selection bias) Low risk Judgement comment: central randomisa-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote “The Physicians’ Health Study
(PHS II) was a randomised, double-blind,
placebo-controlled, factorial trial evaluat-
ing a daily multivitamin (Centrum Silver),
alternate day vitamin E (400 IU synthetic
α-tocopherol), and daily vitamin C (500
mg synthetic ascorbic acid) in the preven-
tion of cancer and CVD among 14,641
male physicians aged 50 years and older.”
Blinding of outcome assessment (detection
bias)
AMD
Low risk Quote “Random misclassification was re-
duced by the use of medical records to con-
firm the participant reports. Non-random
misclassification was unlikely since medi-
cal records were reviewed by an investigator
(WGC) masked to treatment assignment,
and study participants and treating oph-
thalmologists and optometrists were simi-
larly unaware of treatment assignment.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote “Morbidity andmortality follow-up
were extremely high, at 95.3% and 97.9%,
respectively.”
Selective reporting (reporting bias) Low risk Judgement comment: reported AMD out-
comes as expected
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VECAT 2002
Methods Method of allocation: coded bottles
Masking: participant: yes; provider: yes; outcome: yes
Losses to follow-up: not known
Participants Country: Australia
Number of participants randomised: 1204
Eyes: worse eye used as the study eye
Age: 55 to 80 years, mean 66
Sex: 56% female
Inclusion criteria: lens and retina of at least one eye available for documentation
Exclusion criteria: previous cataract surgery or advanced cataract in both eyes; steroid or
anticoagulation use; serious disease; regular use or sensitivity to vitamin E
Interventions Intervention:
• vitamin E (500 IU/day) natural vitamin E in soybean oil medium N = 595
randomised, 587 followed up
Comparator:
• placebo identical in sight, taste and smell N = 598 randomised, 592 followed up
Duration: 4 years
Outcomes 2m logMAR visual acuity; clinical examination; colour stereoscopic fundus photographs
graded using International Grading Scheme
Quote “Participants were categorised by their worse eye.”
Notes Funding source: Quote “The VECAT study was funded in part by grants from the
National Health and Medical Research Council, the Jack Brockhoff Foundation, the
Eirene Lucas Foundation, the Stoicesco Foundation, the Carleton Family Charitable
Trust, JeHope Knell Trust Fund, Smith and Nephew, Australia, and Henkel Australia”
Declarations of interest: none declared
Date study conducted: January 1995 to April 1996
Trial id: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “This random allocation was per-
formed by using a “permuted blocks” allo-
cation scheme”
Allocation concealment (selection bias) Low risk Quote “Study numbers were allocated se-
quentially by the study coordinator as par-
ticipants were enrolled in the study. Par-
ticipants were then randomly allocated to
treatment group. The allocation list was
stored at a remote site.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote “Participants randomly received ei-
ther 500 IU natural vitamin E (335 mg dá
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VECAT 2002 (Continued)
tocopherol) in a soybean oil suspension en-
capsulated in gelatin or a matched placebo
capsule containing only the soybean oil.” [.
..] “Bulk medications were dispensed into
labelled jars by a person not involved in
the study. Vitamin E and placebo were dis-
pensed on different days to avoid confu-
sion. Identical containers were used. The
jars were packed in numerical order and
then dispensed by study personnel. Vita-
min E and placebo capsules were of iden-
tical appearance and taste. Neither study
staff nor examiners or participants were
aware of the treatment allocation, although
all knew that participants would be ran-
domly assigned to receive either vitamin E
or placebo.”
Blinding of outcome assessment (detection
bias)
AMD
Low risk Quote “Neither study staff nor examiners
or participants were aware of the treatment
allocation, although all knew that partici-
pants would be randomly assigned to re-
ceive either vitamin E or placebo.” “At the
end of the study we reassessed the initial
and final photographs for any change with
a “side by side” comparison in a masked
and randomised fashion”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote “From the 1906 people who were
screened by telephone, 1289 (69%) were
examined and 1204 (93%) of these were
enrolled and randomised. We excluded 11
participants after randomisation as they
were outside the required age range at en-
rolment.”
“In the vitamin E group, eight people were
excluded from final data analysis: six de-
veloped diabetic retinopathy, one had my-
opic degeneration, and one had missing
data. Six people were excluded from the
placebo group: two developed adult vitel-
liform macular degeneration and four had
missing data.”
Figure 3: 1204 randomised, 11 excluded af-
ter randomisation, 14 excluded from anal-
ysis: 8/595 vitamin E group and 6/598
placebo group
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VECAT 2002 (Continued)
Selective reporting (reporting bias) Low risk Judgement comment: AMD incidence and
progression reported but no difference be-
tween groups; visual acuity not reported
but “Analysis of best corrected visual acuity
and visual function data showed no differ-
ences between the groups (data not shown)
.” Therefore, no evidence that outcomes
with “better” results selectively reported
WHS 2010
Methods Method of allocation: random allocation of coded bottles
Masking: participant: yes; provider: yes; outcome: yes
Losses to follow-up: not known
Participants Country: USA
Number of participants randomised: 39,876 women health professionals
Age: 45+
Sex: female
Inclusion/exclusion criteria: (a) Female; (b) aged 45 years or older; (c) postmenopausal or
with no intention of becoming pregnant; (d) no reported personal history of cardiovas-
cular disease, cancer (other than non-melanoma skin cancer), gout, peptic ulcer, chronic
renal or liver disease, or other serious illness precluding participation; (e) no reported
history of serious side effects to the study treatments; (f ) not currently taking aspirin,
aspirin containing medication, or nonsteroidal anti-inflammatory drugs (NSAIDs)more
than 1 day per week or, if so doing, willing to forego use of these medications; (g) not
currently taking individual supplements of vitamin E or beta-carotene more than 1 day
per week; (h) not currently taking anticoagulants or corticosteroids
Interventions Intervention:
• vitamin E (600 IU on alternate days) N = 19,697
Comparator:
• placebo N = 19,724
Outcomes Self-report and review of medical records
Quote “Individuals, rather than eyes, were the unit of analysis because eyes were not
examined independently, and participants were classified according to the status of the
worse eye as defined by disease severity. When the worse eye was excluded because of
visual acuity loss attributed to other ocular abnormalities, the fellow eye was considered
for classification.”
Notes Funding source: Quote “Supported by research grants CA 47988, HL 43851, and EY
06633 from the National Institutes of Health, Bethesda, Md. Pills and packaging were
provided by Bayer Healthcare and the Natural Source Vitamin E Association. Bayer
Healthcare and the Natural Source Vitamin E Association had no role in the design and
conduct of the study, in the collection, analysis, and interpretation of the data, or in the
preparation, review, or approval of the manuscript.”
Declarations of interest: Quote “The authors have no proprietary or commercial interest
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WHS 2010 (Continued)
in any materials discussed in this article.”
Date study conducted: August 1993 to March 2004
Trial id: NCT00000161
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “TheWHS was a randomised, dou-
ble-blind, placebo-controlled, 2 x 2 facto-
rial trial...” “Randomization used blocks of
size 16 within 5-year age strata and took
place fromApril 30, 1993, through January
24, 1996.”
Allocation concealment (selection bias) Low risk Quote “TheWHS was a randomised, dou-
ble-blind, placebo-controlled, 2 x 2 facto-
rial trial...”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote “Study medications and end-point
ascertainment were continued in a blinded
fashion through the scheduled end of the
trial (March 31, 2004).” “Pill taking and
end point ascertainment were continued in
blinded fashion through the scheduled end
of the trial on March 31, 2004. Morbidity
and mortality follow-up were 97.2% and
99.4% complete, respectively.”
Blinding of outcome assessment (detection
bias)
AMD
Low risk Quote “Study medications and end-point
ascertainment were continued in a blinded
fashion through the scheduled end of the
trial (March 31, 2004).” “Pill taking and
end point ascertainment were continued in
blinded fashion through the scheduled end
of the trial on March 31, 2004. Morbidity
and mortality follow-up were 97.2% and
99.4% complete, respectively.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote “Compliance (defined as taking at
least two thirds of the study capsules) was
78.9% at 5 years and 71.6% at 10 years,
and averaged 75.8% throughout the trial.”
“Pill taking and end point ascertainment
were continued in blinded fashion through
the scheduled end of the trial onMarch 31,
2004. Morbidity and mortality follow-up
were 97.2% and 99.4% complete, respec-
tively.”
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WHS 2010 (Continued)
Follow-up balanced across treatment
groups. See figure 1.
Selective reporting (reporting bias) Low risk No evidence of selective reporting. The
outcome was limited to the study design
- medical record review. Primary and sec-
ondary outcomes were apparently defined
a priori and were reported
AMD: age-related macular degeneration
ETDRS: Early Treatment Diabetic Retinopathy Study
IU: international units
RPE: retinal pigment epithelium
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ADSC 1997 No published data on AMD. No response from author.
Andrews 1969 No published data on AMD. Unable to contact author.
AREDS 2001 Age-related maculopathy outcomes for people without age-related maculopathy at baseline were not
reported
AREDS2 2008 Participants had AMD
Benner 1994 No published data on AMD. No response from author.
Benton 1995 No data on AMD collected
Berrow 2016 No data on AMD collected
Blok 1997 No data on AMD collected
Bogden 1990 No published data on AMD. No response from author.
Bone 2010 Biological availability study only
Brewer 1997 No published data on AMD. No response from author.
Brown 1998 No published data on AMD. No response from author.
Bussey 1982 No published data on AMD. No response from author.
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(Continued)
Caligiuri 1997 No published data on AMD. No response from author.
CARET 1996 No data on AMD collected
CARMIS 2011 Study on people with AMD (non-advanced AMD), therefore, not on prevention in healthy people
CCSG 1993 No published data on AMD. No response from author.
Chandra 1992 No published data on AMD. No response from author.
CHAOS 1996 No data on AMD collected
Clausen 1989 No published data on AMD. No response from author.
Constans 1996 No published data on AMD. No response from author.
Constantino 1988 No data on AMD collected
Cucinotta 1994 No published data on AMD. No response from author.
DATATOP 1989 No published data on AMD. Unable to contact author.
De Klerk 1998 No data on AMD collected
DeCosse 1989 No published data on AMD. No response from author
Dobson 1984 No data on AMD collected
ECP-IM 1995 No published data on AMD. No response from author.
EUROSCAN 1994 No published data on AMD. No response from author.
Fairley 1996 No published data on AMD. No response from author.
Falsani 2010 Participants had early AMD
Fontham 1995 No data on AMD collected
Galan 1997 No published data on AMD. No response from author.
Garawal 1995 No published data on AMD. No response from author.
GISSI 1993 No published data on AMD. No response from author.
HOPE 1996 No data on AMD collected
Johnson 1997 No published data on AMD. No response from author.
44Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Jyothirmayi 1996 No published data on AMD. No response from author.
Kuklinski 1994 No published data on AMD. No response from author.
Kvansakul 2006 No AMD outcomes
Leng 1997 No published data on AMD. Unable to contact author.
Li 1992 No published data on AMD. No response from author.
LINXIAN 1993 No published data on AMD. No response from author.
Mayne 1998 No data on AMD collected
McKeown 1988 No data on AMD collected
Meyskens 1994 No published data on AMD. No response from author.
Munoz 1987 No published data on AMD. No response from author.
Munoz 1996 No published data on AMD. No response from author.
Nambour 1995 No follow-up data on AMD collected
NCT00000161 (WAFACS) Reported on folic acid, pyridoxine and cyanocobalamin combination treatment
NCT00718653 Study of macular pigment only
NCT00893724 Study on people with AMD
NCT01208948 No AMD outcomes
Newsome, 2008 Study on people with AMD
NPCSG 1996 No published data on AMD. No response from author.
Pastorino 1991 No published data on AMD. No response from author.
Pemp 2010 Study of ocular blood flow and endothelial function only in model of oxidative stress in health
volunteers
Peng 1993 No published data on AMD. No response from author.
PPP 1996 No published data on AMD. No response from author.
PPSG 1994 No data on AMD collected
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(Continued)
Prasad 1995 No published data on AMD. No response from author.
REACT 1995 No published data on AMD. No response from author.
Recchia 1995 No published data on AMD. No response from author.
Rein 2007 Study not a randomised controlled trial
Ret Pig 1993 No published data on AMD. No response from author
Rodriguez-Carmona 2006 No AMD outcomes
SCPS 1989 No data on AMD collected
SECURE 1996 No published data on AMD. No response from author.
Shandong 1998 No data on AMD collected
Sharma 1989 No published data on AMD. No response from author.
Steiner 1995 No published data on AMD. No response from author.
SUVIMAX 1997 No published data on AMD. No response from author.
SWSCPSG 1997 No data on AMD collected
Takamatsu 1995 No published data on AMD. No response from author.
Tomeo 1995 No published data on AMD. No response from author.
Tsubono 1997 No data on AMD collected
Wahlqvist 1994 No data on AMD collected
Wong 2010 Participants had geographic atrophy
Wright 1985 No published data on AMD. No response from author.
Yu 1991 No published data on AMD. No response from author.
YUNNAN 1990 No published data on AMD. No response from author.
Zaridze 1993 No published data on AMD. No response from author.
AMD: age-related macular degeneration
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Characteristics of ongoing studies [ordered by study ID]
NCT01269697 (LIMPIA)
Trial name or title Lutein influence on macula of persons issued from AMD parents
Methods Multicentre, double-masked, randomised clinical trial of supplementation with ’Nutrof Total’ (lutein and
zeaxanthin) versus placebo
Participants People at high genetic risk for AMD because their parents had AMD. Age 40 to 70 years
Interventions Nutrof Total or placebo
Outcomes Primary outcome measure:
Macular pigment density at 6 months after supplementation
Secondary outcome measures:
Best corrected visual acuity 12 months
Cognitive ability 12 months
Plasma fatty acids 12 months
Macular pigment density during supplementation and after stopping supplementation
Starting date -
Contact information Jean-Francois Korobelnik
jean-francois.korobelnik@chu-bordeaux.fr
Notes clinicaltrials.gov/show/NCT01269697
The principal Investigator was contacted in March 2016 and confirmed that the study should be published
in the next year
SELECT
Trial name or title Selenium and Vitamin E Cancer Prevention Trial (SELECT) for prostate cancer
Methods This is a randomised, double-masked, multi-centre study. Participants are randomised to one of 4 prevention
arms:
Arm I: participants receive 2 different oral placebos once daily
Arm II: participants receive oral selenium and oral placebo once daily
Arm III: participants receive oral vitamin E and oral placebo once daily
Arm IV: participants receive oral selenium and oral vitamin E once daily
Treatment continues for 7 to 12 years in the absence of unacceptable toxicity or diagnosis of prostate cancer
Quality of life is assessed at baseline and then at 1, 3, 5, and 7 years
Participants are followed annually
Participants Healthy male volunteers. A total of 32,400 participants (8100 per prevention arm) will be accrued for this
study within 5 years
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SELECT (Continued)
Interventions Dietary supplement: selenium
Dietary supplement: vitamin E
Outcomes Primary outcome measures:
Effect on the clinical incidence of cancer
Effect on cancer-free survival, overall survival and serious cardiovascular events
Quality of life
Association of biological molecular markers with cancer risk
Relationship between effects on cancer risk and genetic factors
Effects in terms of intake of other nutrients, foods and dietary supplements
Effect of other dietary nutrients and dietary patterns on cancer risk
Effects on the reduction of Alzheimer’s disease incidence
Reduction in the risk of AMD or cataract
Starting date July 2001
Contact information -
Notes clinicaltrials.gov/show/NCT00006392
We contacted the principal investigator in March 2016; data collection and analysis of AMD outcomes is still
ongoing
WACS
Trial name or title Women’s Antioxidant Cardiovascular Study
Methods -
Participants 8171 female health professionals aged 40+ with pre-existing cardiovascular disease (CVD) or high risk for
developing CVD
Interventions 2 x 2 x 2 x 2 factorial design:
Vitamin E (600 IU on alternate days)
Vitamin C (500 mg daily)
Beta-carotene (5 mg on alternate days)
Combination of folate (800 mg daily), vitamin B6 (25 mg daily) and vitamin B12 (1 mg daily)
Outcomes Self-report and review of medical records
Starting date 1993
Contact information -
Notes clinicaltrials.gov/show/NCT00000541
We contacted the principal investigator in March 2016; no reply as yet
AMD: age-related macular degeneration
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D A T A A N D A N A L Y S E S
Comparison 1. Vitamin E versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Any AMD 4 55614 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.90, 1.06]
2 Late AMD (either neovascular
AMD or geographic atrophy or
both)
4 55614 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.89, 1.67]
3 Neovascular AMD or geographic
atrophy separately
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Neovascular AMD 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Geographic atrophy 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Beta-carotene versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Any AMD 2 22083 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.88, 1.14]
2 Late AMD (either neovascular
AMD or geographic atrophy or
both)
2 22083 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.65, 1.24]
3 Neovascular AMD or geographic
atrophy separately
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Neovascular AMD 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Geographic atrophy 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Vitamin C versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 AMD 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Any AMD 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Late AMD (either
neovascular AMD or
geographic atrophy or both)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 4. Multivitamin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 AMD 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Any AMD 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Late AMD (either
neovascular AMD or
geographic atrophy or both)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Vitamin E versus placebo, Outcome 1 Any AMD.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 1 Vitamin E versus placebo
Outcome: 1 Any AMD
Study or subgroup Vitamin E Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 1998 (1) 148/494 121/447 14.1 % 1.11 [ 0.90, 1.36 ]
PHS II 2012 (2) 176/7112 187/7124 20.7 % 0.94 [ 0.77, 1.16 ]
VECAT 2002 (3) 280/504 279/512 30.6 % 1.02 [ 0.91, 1.14 ]
WHS 2010 (4) 280/19697 313/19724 34.6 % 0.90 [ 0.76, 1.05 ]
Total (95% CI) 27807 27807 100.0 % 0.97 [ 0.90, 1.06 ]
Total events: 884 (Vitamin E), 900 (Placebo)
Heterogeneity: Chi2 = 3.34, df = 3 (P = 0.34); I2 =10%
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours vitamin E Favours placebo
(1) Average duration of treatment and follow-up: 6 years
(2) Average duration of treatment and follow-up: 8 years
(3) Average duration of treatment and follow-up: 4 years
(4) Average duration of treatment and follow-up: 10 years
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Analysis 1.2. Comparison 1 Vitamin E versus placebo, Outcome 2 Late AMD (either neovascular AMD or
geographic atrophy or both).
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 1 Vitamin E versus placebo
Outcome: 2 Late AMD (either neovascular AMD or geographic atrophy or both)
Study or subgroup Vitamin E Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 1998 (1) 11/494 3/447 4.4 % 3.32 [ 0.93, 11.82 ]
PHS II 2012 (2) 42/7112 38/7124 53.4 % 1.11 [ 0.71, 1.71 ]
VECAT 2002 (3) 5/504 4/512 5.6 % 1.27 [ 0.34, 4.70 ]
WHS 2010 (4) 29/19697 26/19724 36.6 % 1.12 [ 0.66, 1.90 ]
Total (95% CI) 27807 27807 100.0 % 1.22 [ 0.89, 1.67 ]
Total events: 87 (Vitamin E), 71 (Placebo)
Heterogeneity: Chi2 = 2.68, df = 3 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours vitamin E Favours placebo
(1) Average duration of treatment and follow-up: 6 years
(2) Average duration of treatment and follow-up: 8 years
(3) Average duration of treatment and follow-up: 4 years
(4) Average duration of treatment and follow-up: 10 years
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Analysis 1.3. Comparison 1 Vitamin E versus placebo, Outcome 3 Neovascular AMD or geographic atrophy
separately.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 1 Vitamin E versus placebo
Outcome: 3 Neovascular AMD or geographic atrophy separately
Study or subgroup Vitamin E Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Neovascular AMD
ATBC 1998 (1) 8/494 2/447 3.62 [ 0.77, 16.95 ]
2 Geographic atrophy
ATBC 1998 (2) 3/494 1/447 2.71 [ 0.28, 26.00 ]
0.05 0.2 1 5 20
Favours vitamin E Favours placebo
(1) Average duration of treatment and follow-up: 6 years
(2) Average duration of treatment and follow-up: 6 years
Analysis 2.1. Comparison 2 Beta-carotene versus placebo, Outcome 1 Any AMD.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 2 Beta-carotene versus placebo
Outcome: 1 Any AMD
Study or subgroup Beta-carotene Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 1998 (1) 141/491 128/450 32.7 % 1.01 [ 0.82, 1.24 ]
PHS I 2007 (2) 275/10585 274/10557 67.3 % 1.00 [ 0.85, 1.18 ]
Total (95% CI) 11076 11007 100.0 % 1.00 [ 0.88, 1.14 ]
Total events: 416 (Beta-carotene), 402 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours beta-carotene Favours placebo
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(1) Average duration of treatment and follow-up: 6 years
(2) Average duration of treatment and follow-up: 12 years
Analysis 2.2. Comparison 2 Beta-carotene versus placebo, Outcome 2 Late AMD (either neovascular AMD
or geographic atrophy or both).
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 2 Beta-carotene versus placebo
Outcome: 2 Late AMD (either neovascular AMD or geographic atrophy or both)
Study or subgroup Beta-carotene Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 1998 (1) 5/491 9/450 12.4 % 0.51 [ 0.17, 1.51 ]
PHS I 2007 (2) 63/10585 66/10557 87.6 % 0.95 [ 0.67, 1.34 ]
Total (95% CI) 11076 11007 100.0 % 0.90 [ 0.65, 1.24 ]
Total events: 68 (Beta-carotene), 75 (Placebo)
Heterogeneity: Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours beta-carotene Favours placebo
(1) Average duration of treatment and follow-up: 6 years
(2) Average duration of treatment and follow-up: 12 years
53Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.3. Comparison 2 Beta-carotene versus placebo, Outcome 3 Neovascular AMD or geographic
atrophy separately.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 2 Beta-carotene versus placebo
Outcome: 3 Neovascular AMD or geographic atrophy separately
Study or subgroup Beta-carotene Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Neovascular AMD
ATBC 1998 (1) 4/491 6/450 0.61 [ 0.17, 2.15 ]
2 Geographic atrophy
ATBC 1998 (2) 1/491 3/450 0.31 [ 0.03, 2.93 ]
0.05 0.2 1 5 20
Favours beta-carotene Favours placebo
(1) Average duration of treatment and follow-up: 6 years
(2) Average duration of treatment and follow-up: 6 years
Analysis 3.1. Comparison 3 Vitamin C versus placebo, Outcome 1 AMD.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 3 Vitamin C versus placebo
Outcome: 1 AMD
Study or subgroup Vitamin C Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any AMD
PHS II 2012 (1) 179/7149 184/7087 0.96 [ 0.79, 1.18 ]
2 Late AMD (either neovascular AMD or geographic atrophy or both)
PHS II 2012 (2) 39/7149 41/7087 0.94 [ 0.61, 1.46 ]
0.5 0.7 1 1.5 2
Favours vitamin C Favours placebo
(1) Average treatment duration and follow-up: 8 years
(2) Average treatment duration and follow-up: 8 years
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Analysis 4.1. Comparison 4 Multivitamin versus placebo, Outcome 1 AMD.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 4 Multivitamin versus placebo
Outcome: 1 AMD
Study or subgroup Multivitamin Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any AMD
PHS II 2012 (1) 294/7111 244/7122 1.21 [ 1.02, 1.43 ]
2 Late AMD (either neovascular AMD or geographic atrophy or both)
PHS II 2012 (2) 79/7111 65/7122 1.22 [ 0.88, 1.69 ]
0.5 0.7 1 1.5 2
Favours multivitamin Favours placebo
(1) Average duration of treatment and follow-up: 11 years
(2) Average duration of treatment and follow-up: 11 years
A D D I T I O N A L T A B L E S
Table 1. Mapping the definition of AMD used in included studies to the review outcomes
Definition of AMD used in
this review
Study
ATBC 1998 PHS I 2007 PHS II 2012;
WHS 2010
VECAT 2002
No AMD 0 = no ARM Did not self-report or no signs
listed below in medical records
-
Any AMD I = dry maculopathy, with hard
drusen, pigmentary changes, or
both
II = soft macular drusen
III = disciform degeneration
IV = geographic atrophy.
Drusen, RPE hypo or hyper-
pigmentation, geographic atro-
phy, RPE detachment, subreti-
nal neovascular membrane,
or disciform scar
Early AMD 1: Soft intermedi-
ate or soft distinct or soft indis-
tinct or pigment changes (hy-
perpigmentation or hypopig-
mentation)
Early AMD 2: Soft intermedi-
ate or soft distinct or soft indis-
tinct and pigment changes (hy-
perpigmentation or hypopig-
mentation)
Early AMD 3: Soft distinct
or soft indistinct or pigment
changes (hyperpigmentation or
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Table 1. Mapping the definition of AMD used in included studies to the review outcomes (Continued)
hypopigmentation)
Early AMD 4: Soft distinct
or soft indistinct and pigment
changes (hyperpigmentation or
hypopigmentation)
Late AMD: Serous or haemor-
rhagic detachment of the RPE
or sensory retina, characteris-
tic haemorrhages, or subreti-
nal fibrous scars, central are-
olar zone of retinal pigment
epithelial atrophy with visible
choroidal vessels, at least 175
µm in diameter
Late AMD III = disciform degeneration
IV = geographic atrophy.
Geographic atrophy, RPE de-
tachment, subretinal neovascu-
lar membrane, or disciform scar
Serous or haemorrhagic detach-
ment of the RPE or sensory
retina, characteristic haemor-
rhages, or subretinal fibrous
scars, central areolar zone of
retinal pigment epithelial atro-
phy with visible choroidal
vessels, at least 175 µm in diam-
eter
Neovascular AMD III = disciform degeneration RPE detachment, subretinal
neovascular membrane, or dis-
ciform scar
Serous or haemorrhagic detach-
ment of the RPE or sensory
retina, characteristic haemor-
rhages, or subretinal fibrous
scars
Geographic atrophy IV = geographic atrophy. Geographic atrophy Central areolar zone of retinal
pigment epithelial atrophy with
visible choroidal
vessels, at least 175 µm in diam-
eter, in the absence of signs of
neovascular AMD in the same
eye
RPE: retinal pigment epithelial
Method of detection: Grading of fundus photographs (ATBC 1998; VECAT 2002), and medical record review after self-report of
AMD diagnosis (PHS I 2007; PHS II 2012; WHS 2010)
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Macular Degeneration
#2 MeSH descriptor Retinal Degeneration
#3 MeSH descriptor Retinal Neovascularization
#4 MeSH descriptor Choroidal Neovascularization
#5 MeSH descriptor Macula Lutea
#6 macula* near lutea*
#7 (macula* or retina* or choroid*) near/4 degenerat*
#8 (macula* or retina* or choroid*) near/4 neovascul*
#9 maculopath*
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11 MeSH descriptor Vitamins
#12 vitamin*
#13 MeSH descriptor Vitamin A
#14 retinol*
#15 MeSH descriptor beta Carotene
#16 caroten*
#17 MeSH descriptor Ascorbic Acid
#18 ascorbic next acid
#19 MeSH descriptor Vitamin E
#20 MeSH descriptor alpha-Tocopherol
#21 alpha tocopherol*
#22 MeSH descriptor Vitamin B 12
#23 cobalamin*
#24 MeSH descriptor Antioxidants
#25 antioxidant* or anti oxidant*
#26 MeSH descriptor Carotenoids
#27 carotenoid*
#28 MeSH descriptor Zinc
#29 zinc*
#30 MeSH descriptor Riboflavin
#31 riboflavin*
#32 MeSH descriptor Selenium
#33 selenium*
#34 MeSH descriptor Lutein
#35 lutein*
#36 MeSH descriptor Xanthophylls
#37 xanthophyll*
#38 zeaxanthin*
#39 (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24)
#40 (#25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38)
#41 (#39 OR #40)
#42 (#10 AND #41)
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Appendix 2. MEDLINE Ovid search strategy
1. exp clinical trial/ [publication type]
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp macular degeneration/
14. exp retinal degeneration/
15. exp retinal neovascularization/
16. exp choroidal neovascularization/
17. exp macula lutea/
18. maculopath$.tw.
19. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
20. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
21. (macula$ adj2 lutea).tw.
22. or/13-21
23. exp vitamins/
24. exp vitamin A/
25. vitamin A.tw.
26. retinol$.tw.
27. exp beta carotene/
28. caroten$.tw.
29. exp ascorbic acid/
30. ascorbic acid$.tw.
31. vitamin C.tw.
32. exp Vitamin E/
33. exp alpha tocopherol/
34. alpha?tocopherol$.tw.
35. alpha tocopherol$.tw.
36. vitamin E.tw.
37. exp Vitamin B12/
38. vitamin B12.tw.
39. cobalamin$.tw.
40. exp antioxidants/
41. ((antioxidant$ or anti) adj1 oxidant$).tw.
42. exp carotenoids/
43. carotenoid$.tw.
44. exp zinc/
45. zinc$.tw.
46. exp riboflavin/
47. riboflavin$.tw.
48. exp selenium/
49. selenium$.tw.
50. exp lutein/
51. lutein$.tw.
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52. exp xanthophylls/
53. xanthophyll.tw.
54. zeaxanthin$.tw.
55. or/23-54
56. 22 and 55
57. 12 and 56
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase Ovid search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina macula degeneration/
34. exp retina degeneration/
35. exp retina neovascularization/
36. exp subretinal neovascularization/
37. maculopath$.tw.
38. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
39. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
40. exp retina macula lutea/
41. (macula$ adj2 lutea$).tw.
42. or/33-41
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43. exp vitamins/
44. exp Retinol/
45. vitamin A.tw.
46. retinol$.tw.
47. exp beta carotene/
48. caroten$.tw.
49. exp ascorbic acid/
50. ascorbic acid$.tw.
51. vitamin C.tw.
52. exp alpha tocopherol/
53. alpha?tocopherol$.tw.
54. alpha tocopherol$.tw.
55. vitamin E.tw.
56. vitamin B12.tw.
57. exp cyanocobalamin/
58. cobalamin$.tw.
59. exp antioxidants/
60. ((antioxidant$ or anti) adj1 oxidant$).tw.
61. exp carotenoid/
62. exp zinc/
63. zinc$.tw.
64. exp riboflavin/
65. riboflavin$.tw.
66. exp selenium/
67. selenium$.tw.
68. exp zeaxanthin/
69. zeaxanthin$.tw.
70. lutein$.tw.
71. xanthophyll.tw.
72. or/43-71
73. 42 and 72
74. 32 and 73
Appendix 4. AMED Ovid search strategy
1. exp eye disease/
2. exp vision disorders/
3. exp retinal disease/
4. maculopath$.tw.
5. ((macul$ or retina$ or choroid$) adj3 degenerat$).tw.
6. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
7. or/1-6
8. exp vitamins/
9. vitamin A.tw.
10. retinol$.tw.
11. exp carotenoids/
12. caroten$.tw.
13. exp ascorbic acid/
14. ascorbic acid$.tw.
15. vitamin C.tw.
16. vitamin E.tw.
17. alpha tocopherol$.tw.
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18. vitamin B12.tw.
19. cobalamin$.tw.
20. exp antioxidants/
21. ((antioxidant$ or anti) adj1 oxidant$).tw.
22. zinc/
23. zinc$.tw.
24. riboflavin$.tw.
25. selenium/
26. selenium$.tw.
27. lutein$.tw.
28. xanthophylls.tw.
29. zeaxanthin$.tw.
30. or/8-29
31. 7 and 30
Appendix 5. OpenGrey search strategy
(macular degeneration OR AMD) AND (antioxidant OR vitamin OR carotene OR selenium OR tocopherol)
Appendix 6. ISRCTN search strategy
(macular degeneration OR AMD) AND (antioxidant OR vitamin OR carotene OR selenium OR tocopherol)
Appendix 7. ClinicalTrials.gov search strategy
(Macular Degeneration OR AMD) AND (Antioxidant OR Vitamin OR Carotene OR Selenium OR Tocopherol)
Appendix 8. ICTRP search strategy
Macular Degeneration OR AMD = Condition AND Antioxidant OR Vitamin OR Carotene OR Selenium OR Tocopherol = Inter-
vention
Appendix 9. MEDLINE Ovid adverse effects search strategy
1. exp retinal degeneration/
2. retinal neovascularization/
3. choroidal neovascularization/
4. exp macula lutea/
5. (macula$ adj2 lutea).tw.
6. ((macul$ or retina$ or choroid$) adj4 degener$).tw.
7. ((macul$ or retina$ or choroid$) adj4 neovasc$).tw.
8. (AMD or ARMD or CNV).tw.
9. maculopath$.tw.
10. or/1-9
11. exp vitamins/
12. vitamin A.tw.
13. retinol$.tw.
14. (caroten$ or betacaroten$).tw.
15. ascorbic acid$.tw.
16. vitamin C.tw.
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17. alpha?tocopherol$.tw.
18. alpha tocopherol$.tw.
19. vitamin E.tw.
20. ((antioxidant$ or anti) adj1 oxidant$).tw.
21. zinc/
22. zinc$.tw.
23. or/11-22
24. 10 and 23
25. ae.fs.
26. 24 and 25
27. limit 26 to (meta analysis or randomized controlled trial or “review”)
WH A T ’ S N E W
Last assessed as up-to-date: 29 March 2017.
Date Event Description
30 July 2017 Amended Minor amendment to the updated version of 2017: Cochrane Review Evans 2017 reference amended as
updated version of this review published
H I S T O R Y
Protocol first published: Issue 3, 1997
Review first published: Issue 4, 1999
Date Event Description
29 March 2017 New search has been performed Issue 7, 2017: Electronic searches were updated.
29 March 2017 New citation required but conclusions have not
changed
Issue 7, 2017: One new trial (PHS II 2012), which
has now been completed, was included in the review
update
19 April 2012 New citation required but conclusions have not
changed
2012, Issue 6: The author byline has changed. Kather-
ine Henshaw has been replaced by a new author, John
Lawrenson
19 April 2012 New search has been performed 2012, Issue 6: New searches yielded one new trial. New
’Risk of bias’ grading and a ’Summary of findings’ table
have been included
28 August 2008 Amended Converted to new review format.
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(Continued)
8 November 2007 New citation required and conclusions have changed Substantive amendment. 2008, Issue 1: The results for
PHS I were included. AREDS was previously included
in this review but as no numerical data were available
from the study on prevention of AMD, it was excluded
from the review. The results of AREDS are presented
in the review ’Antioxidants for slowing down the pro-
gression of AMD’
C O N T R I B U T I O N S O F A U T H O R S
JE assessed studies for inclusion and exclusion, assessed risk of bias, extracted data, entered data and wrote the text of the review.
JL assessed studies for inclusion and exclusion, assessed risk of bias, extracted data, and reviewed and commented on the text of the
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D E C L A R A T I O N S O F I N T E R E S T
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Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology.
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The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The original protocol was published in 1999 (Evans 1999). Since that time, there have been methodological improvements within
Cochrane, and the methods have been updated to include assessment of risk of bias, ’Summary of findings’ tables, GRADE assessment,
and better consideration of unit of analysis issues.
For the 2017 update, we modified the outcome measures to ensure they were in line with those being used as part of the macular
degeneration guidelines being prepared by NICE (NICE 2016). In previous versions of this review the outcomes were:
1. number of participants developing AMD;
2. number of participants with visual loss due to AMD;
3. quality of life measures;
4. any adverse outcomes reported.
In previous versions of this review, we pooled all antioxidants into one analysis. This was not possible in the current version because of
overlapping participants in two trials.
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